TY - JOUR
T1 - A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma
AU - Kozuch, Peter
AU - Petryk, Magdalena
AU - Bruckner, Howard W.
PY - 2002
Y1 - 2002
N2 - Phase II trials of combination chemotherapies have shown encouraging palliative benefit, objective response rates, and survival outcomes. Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine. The fixed rate infusion schedule of 10mg/m2/min is gaining wide acceptance and is a promising investigational priority. A very reasonable alternative to single agent gemcitabine, and our bias, is enrollment into clinical trials evaluating novel gemcitabine-based combinations. Further investigation is needed to determine optimal incorporation of so-called targeted therapy with combination chemotherapy.
AB - Phase II trials of combination chemotherapies have shown encouraging palliative benefit, objective response rates, and survival outcomes. Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine. The fixed rate infusion schedule of 10mg/m2/min is gaining wide acceptance and is a promising investigational priority. A very reasonable alternative to single agent gemcitabine, and our bias, is enrollment into clinical trials evaluating novel gemcitabine-based combinations. Further investigation is needed to determine optimal incorporation of so-called targeted therapy with combination chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0036259139&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(01)00004-1
DO - 10.1016/S0889-8588(01)00004-1
M3 - Review article
C2 - 12063823
AN - SCOPUS:0036259139
SN - 0889-8588
VL - 16
SP - 123
EP - 138
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -